TX eco Cable
Biosense Webster, Inc. · Decision date Aug 17, 2026
What did the FDA decide?
FDA records P210027/S017 as a supplement to PMA P210027, with the supplement type “30-Day Notice”. The recorded decision is OK30 (30-day notice), dated Aug 17, 2026.
FDA approval order statement
relocation of manufacturing line within the existing manufacturing facility
- Regulatory pathway
- PMA supplement
- Supplement type
- 30-Day Notice
- Clinical specialty
- Cardiovascular
- Decision date
- Aug 17, 2026
- FDA change category
- Process Change - Manufacturer/Sterilizer/Packager/Supplier
Regulatory record facts
- Identifier
- P210027/S017
- Regulatory pathway
- PMA supplement
- Applicant
- Biosense Webster, Inc.
- Product code
- OAE
- Decision code
- OK30
- Decision date
- Aug 17, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Catheter, percutaneous, cardiac ablation, for treatment of atrial fibrillation.
- Applicant
- Biosense Webster, Inc.
- Product code
- OAE
- FDA device class
- 3
For the original device and its historical approval scope, see PMA P210027. Subsequent supplements may change the device or its indications.
FDA decision timeline
P210027 · Original PMA
QDOT MICRO System
P210027/S016 · Related supplement
QDOT MICRO System
P210027/S017 received
Application receipt date recorded by FDA.
P210027/S017 · FDA decision
30-Day Notice
P210027/S018 · Related supplement
QDOT MICRO System
P210027/S019 · Related supplement
QDOT MICRO BI-DIRECTIONAL NAVIGATION CATHETER; QDOT MICRO UNI-DIRECTIONAL NAVIGATION CATHETER
Timeline entries are records held by MedtechLedger for P210027. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P210027
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
QDOT MICRO SystemP210027 | Biosense Webster, Inc. | PMA approval | Nov 23, 2022 | FDA |
QDOT MICRO SystemP210027/S016 | Biosense Webster, Inc. | PMA supplement | Apr 17, 2026 | FDA |
QDOT MICRO SystemP210027/S018 | Biosense Webster, Inc. | PMA supplement | Sep 10, 2026 | FDA |
| Biosense Webster, Inc. | PMA supplement | Sep 15, 2026 | FDA |
Explore the linked device profile
Other records with product code OAE
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
STOP Persistent AFP100010/S154 | Medtronic Cryocath, LP | PMA supplement | Sep 25, 2026 | FDA |
TactiFlex Ablation Catheter, Sensor EnabledP220013/S034 | ABBOTT MEDICAL | PMA supplement | Sep 22, 2026 | FDA |
| ABBOTT MEDICAL | PMA supplement | Sep 4, 2026 | FDA | |
TactiSys Quartz Equipment; Ampere GeneratorP130026/S102 | St Jude Medical | PMA supplement | Aug 7, 2026 | FDA |
TactiSys Quartz Equipment; Ampere GeneratorP220013/S033 | ABBOTT MEDICAL | PMA supplement | Aug 7, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Biosense Webster, Inc.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 31 Technology Dr., Suite 200, Irvine, CA, 92618
Sources and methodology
- Original FDA record: P210027/S017
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 20, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records





